Suche Infos über Stressgen, Repligen, immunogen - 500 Beiträge pro Seite

[Reichert73]

Wer kennt diese Firmen?

Stressgen # 901062
Repligen # 870980
Immunogen # 878613

Sind diese Aktien kaufenswert?

[SuicideKing]

Habe gehört, daß sich bei Repligen (RGEN, 870980) was anbahnt.
Wenn jamand genaueres weiß, bitte posten.

SK

[pochs]

Hallo habe auch über repligen gute sachen gehört.
ich werde sie auf jeden fall in usa kaufen
habt ihr nähere infos .
danke pochs

[SuicideKing]

Konkrete Infos habe ich auch nicht. Jedoch scheint sich in letzter Zeit
was zu tun bei RGEN. Sie befinden sich meines Erachtens in einem schönen
Aufwertstrend. Derzeit ein sattes plus von 16,19%. Auch hier werde ich
wohl erst mal abwarten bis Ende der Woche und eventuell noch mal nach-
kaufen.

Happy trading

SK

[Busmann]

gute IR abteilung, schicken sogar press updates nach europa rüber...

[Busmann]

Hello, my name is Megan McGonagle and I recently joined Repligen as a Corporate Communications Associate. In the past you have requested literature pertaining to the company however you are not currently on our e-mail list for press release distribution. If you would like me to add you to our list please respond to this e-mail or feel free to contact me at your convenience.

Recent milestones in the clinical development of secretin as a treatment for autism:

ß In April we completed a Phase 2 clinical trial of secretin as a treatment for autism.

ß In September the U.S. Food and Drug Administration (FDA) granted Fast Track designation for secretin for the treatment of pediatric autism.

ß We are currently planning to initiate pivotal Phase 3 trials in early 2002.

ß In November at the Society for Neuroscience and IMFAR we will give 5 oral presentations on the Phase 2 clinical trial results, the neurobiology of secretin in animals, gastrointestinal disease in autism and biological characterization of this patient population.

We are currently conducting a phase 2 clinical trial of CTLA4-Ig in stem cell transplant and we plan to initiate a Phase 2 clinical trial of uridine as a treatment for mitochondrial disease by the end of they year. If you would like more information on any of our clinical programs please don`t hesitate to contact me.

Repligen Corporation develops new drugs for debilitating pediatric disorders including autism, cancer, and immune and metabolic disorders. Repligen also manufactures and markets a set of patented products based on Protein A, which are used by the pharmaceutical industry to
produce therapeutic antibodies.

Regards-

Megan McGonagle

RepliGen Corporation
Corporate Communications Associate
117 Fourth Avenue
Needham, MA 02494
P:781.449.9560 x2023
P:800.622.2259 x2023 (toll free)
F:781.453.1988
[e-mail]
www.repligen.com




vielleicht ist ja jemand interessiert...